The MRKAd5/HIV Step Study employed a replication incompetent adenovirus 5 (Ad5) vector expressing HIV proteins. Surprisingly, vaccinees that were previously Ad5 seropositive had an increased risk of ...

New findings have disproved a leading explanation for why an experimental HIV vaccine made subjects more susceptible to the virus, reopening the door for further HIV vaccine efforts based on similar ...

Did patients in a failed HIV vaccine trial halted in 2007 become more susceptible to the virus due to the adenoviral vector used to deliver the experimental vaccine? Researchers have speculated this ...

(Philadelphia, PA) -- Researchers at the University of Pennsylvania School of Medicine report the first clinical test of a new gene therapy based on a disabled AIDS virus carrying genetic material ...

A gene therapy that uses infusions of patients’ own T cells genetically engineered to attack their tumors enjoyed its first successful and sustained demonstration of clinical-trial success in nine of ...

CHICAGO--(BUSINESS WIRE)--Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to ...

At least 30 vaccines for HIV are in clinical trials to either prevent HIV infection or suppress the development of AIDS. James Laufenberg, president and CEO of ImmunoGenetix Therapeutics, is working ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS ...

Renowned for its focus on developing cutting-edge DNA-based vaccines, Genetic Immunity has built an industry-leading team to deliver its lead candidate, a plasmid DNA HIV vaccine, into a Phase 3 trial ...